Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval

Table 1 Positive and Negative Syndrome Scale (PANSS) Scores at Baseline, Week 52, and Endpoint (Intention-to-Treat Population)

PANSS, mean ± SD	Baseline (N = 67)	Week 52 (n = 31)	LOCF Endpoint (N = 67)
Total	65.4 ± 13.5	57.5 ± 12.7	61.7 ± 17.9
		P < .0001	P = .087
Positive symptoms	18.1 ± 5.3	15.6 ± 4.5	17.3 ± 6.2
		P < .0001	P = .233
Negative symptoms	17.4 ± 5.4	16.0 ± 4.4	16.1 ± 5.4
		P = .007	P = .071
Anxiety/depression	9.1 ± 3.0	7.3 ± 2.7	8.5 ± 3.7
		P = .002	P = .133
Disorganized thought	14.4 ± 4.1	13.4 ± 3.8	13.9 ± 4.2
		P = .001	P = .337
Uncontrolled hostility/excitement	6.3 ± 2.4	5.3 ± 1.7	5.9 ± 2.4
		P = .001	P = .278

P values represent significance of change from baseline, paired t test. LOCF indicates last observation carried forward.

ISSN: 1744-859X